Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors
| Autor: | Yazan Daaboul, Aysha Aslam, C. Michael Gibson, Aravind Reddy Kuchkuntla, Dima Nimri, Anthony Gallo, Gerald Chi, Seyedmahdi Pahlavani, Tarek Nafee, Serge Korjian, Nathan Michalak, Usama Talib |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
medicine.drug_mechanism_of_action medicine.drug_class medicine.medical_treatment Factor Xa Inhibitor Antidotes Hemorrhage 030204 cardiovascular system & hematology Pharmacology Anticoagulant activity 03 medical and health sciences 0302 clinical medicine Internal Medicine Medicine Humans In patient 030212 general & internal medicine Antidote Blood Coagulation business.industry Anticoagulant Anticoagulants General Medicine Recombinant Proteins Surgery Clinical trial Coagulation Factor Xa Cardiology and Cardiovascular Medicine business Andexanet alfa medicine.drug Factor Xa Inhibitors |
| Zdroj: | Expert review of cardiovascular therapy. 15(4) |
| ISSN: | 1744-8344 |
| Popis: | Andexanet alfa is a recombinant factor Xa decoy molecule that inhibits direct and indirect factor Xa inhibitors to allow the normal coagulation process to resume. Its development arises in a space where novel oral anticoagulants are receiving expanded indications yet their use is limited by the lack of an effective reversal agent. Areas covered: This article reviews the biochemical properties, mechanism of action and the preclinical and clinical trials on andexanet alfa. It additionally aims to provide expert commentary and future perspectives on the efficacy, safety and challenges facing andexanet alfa as a universal antidote for direct and indirect factor Xa inhibitors. Expert commentary: Andexanet alfa shows promise to become a highly effective, novel antidote for factor Xa anticoagulation. Its biochemical profile and mechanism of action are immediately more attractive than other drugs on the market and under development due to its inert nature within the normal coagulation cascade, with minimal intrinsic procoagulant or anticoagulant properties. The anticoagulant antidote space will continue to develop as more specific and universal options become available for reversal of the effect of DOACs. Preliminary results of a pivotal phase 3b/4 trial demonstrate a favorable efficacy and safety profile in patients with acute hemorrhage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|